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Abstract
Background: Multiple studies of tuberculosis treatment have indicated that patients with diabetes mellitus may
experience poor outcomes.
We performed a systematic review and meta-analysis to quantitatively summarize evidence for the impact of
diabetes on tuberculosis outcomes.
Methods: We searched PubMed, EMBASE and the World Health Organization Regional Indexes from 1 January
1980 to 31 December 2010 and references of relevant articles for reports of observational studies that included
people with diabetes treated for tuberculosis. We reviewed the full text of 742 papers and included 33 studies of
which 9 reported culture conversion at two to three months, 12 reported the combined outcome of failure and
death, 23 reported death, 4 reported death adjusted for age and other potential confounding factors, 5 reported
relapse, and 4 reported drug resistant recurrent tuberculosis.
Results: Diabetes is associated with an increased risk of failure and death during tuberculosis treatment. Patients
with diabetes have a risk ratio (RR) for the combined outcome of failure and death of 1.69 (95% CI, 1.36 to 2.12).
The RR of death during tuberculosis treatment among the 23 unadjusted studies is 1.89 (95% CI, 1.52 to 2.36), and
this increased to an effect estimate of 4.95 (95% CI, 2.69 to 9.10) among the 4 studies that adjusted for age and
other potential confounding factors. Diabetes is also associated with an increased risk of relapse (RR, 3.89; 95% CI,
2.43 to 6.23). We did not find evidence for an increased risk of tuberculosis recurrence with drug resistant strains
among people with diabetes. The studies assessing sputum culture conversion after two to three months of
tuberculosis therapy were heterogeneous with relative risks that ranged from 0.79 to 3.25.
Conclusions: Diabetes increases the risk of failure and death combined, death, and relapse among patients with
tuberculosis. This study highlights a need for increased attention to treatment of tuberculosis in people with
diabetes, which may include testing for suspected diabetes, improved glucose control, and increased clinical and
therapeutic monitoring.
Background
Tuberculosis (TB) remains a major source of morbidity
and mortality throughout the world; one-third of the
world’s population is estimated to be infected with
Mycobacterium tuberculosis, approximately nine million
people develop the disease each year, and almost two
million die annually from the disease [1,2]. Epidemiolo-
gical studies have elucidated an association between dia-
betes mellitus (DM) and the development of TB disease
[3-7]. According to a recent systematic review, among
cohort studies, people with DM had approximately three
times the risk of developing TB disease as people with-
out [4]. The global burden of DM is rising; the preva-
lence is estimated to reach 438 million by 2030, and
more than 80% of the adult cases will be in newly devel-
oped or developing countries [8]. The convergence of
these two epidemics may lead to an increased incidence
of TB disease, especially in low and middle income
countries with increasing numbers of people with DM
and prevalent TB disease [5,9]. For example, in areas
such as the border population of South Texas and
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is the most common risk factor associated with TB [10].
Among patients afflicted with both TB and DM, dia-
betes is reported to be associated with poor TB treat-
ment outcomes [7,11,12]; however, a systematic analysis
to both clarify and quantify the association between DM
and TB outcomes, including persistence of sputum cul-
ture positivity, failure, death and relapse, has not been
performed. Given the increasing burden of TB patients
with DM globally, an association between DM and TB
outcomes would suggest that diabetes could increase the
number of persons infected by a source case and the
number of patients needing anti-TB retreatment regi-
mens. Further clarification and quantification of the
association between DM and these outcomes will inform
public health measures, and we conducted a systematic
review and meta-analysis to this end.
Methods
We conducted this study according to the Meta-analysis
of Observational Studies in Epidemiology (MOOSE)
guidelines [13].
Data sources and searches
We searched the PubMed via the NCBI Entrez system
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi, the
EMBASE via Ovid http://www.ovid.com, and the World
Health Organization Regional Indexes (AIM (AFRO),
LILACS (AMRO/PAHO), IMEMR (EMRO), IMSEAR
(SEARO), WPRIM (WPRO)) http://www.globalhealthli-
brary.net/php/index.phpf r o m1J a n u a r y1 9 8 0t o3 1
December 2010 for studies of the association between
DM and TB disease outcomes. We also searched biblio-
graphies of identified reports for additional references.
Our search strategy is defined in Panel 1.
Panel 1. Search strategy for studies on the association
between DM and TB outcomes
PubMed:
MeSH Terms:
1. Tuberculosis
2. “Diabetes mellitus”
Text Terms:
3. Outcome(s) OR Treatment(s)
4. Risk factor(s)
5. Tuberculosis
6. “Diabetes mellitus”
Search Strings (all inclusive)
a) 1 AND 2
b) 1 AND 3 AND 4
c) 5 AND 6 (for the year preceding 12/10 in
which articles may not have been assigned
MeSH terms)
EMBASE and World Health Organization Regional
Indexes:
1. Tuberculosis, major subject
2. “Diabetes mellitus”
3. Outcome(s) OR Treatment(s)
4. Risk factor(s)
Search Strings (all inclusive)
a) 1 AND 2
b) 1 AND 3 AND 4
Study selection
We included studies regardless of language. We com-
pared sources to exclude duplicate references and con-
tacted authors for data that were not available in
publications and abstracts. Studies were included if they
met the following criteria: 1) They were peer-reviewed
reports of studies involving human participants receiving
pharmacologic anti-mycobacterial treatment for TB dis-
ease. 2) They provided or permitted the computation of
an effect estimate of the relationship between DM and
at least one of the following five TB treatment out-
comes: proportion of treated patients who experienced
culture conversion at two to three months, the com-
bined outcome of treatment failure and death, death,
relapse, or recurrence with drug-resistant (DR) TB.
Treatment failure was defined as sputum smear or cul-
ture positivity at five months or later during treatment
[14,15]. We combined failure and death into a single
endpoint that represents poor outcomes. Death was
defined as death for any reason during the course of
treatment [14-16]. Relapse was defined as bacteriologi-
cally positive TB disease that occurred after a patient
was considered to have completed treatment or to have
been cured [14-16]. Recurrence was defined as TB dis-
ease that occurred in a patient with a history of prior
treatment for TB. 3) They defined DM as any of the fol-
lowing: baseline diagnosis by self-report, medical
records, fasting blood glucose (FBG) ≥ 126 mg/dL or ≥
140 mg/dL (to reflect the present and past American
Diabetes Association Guidelines and World Health
Organization (WHO) recommendations for the diagno-
sis of DM [17,18]), non-FBG ≥ 200 mg/dL, or treatment
with oral hypoglycemic medications or insulin.
We excluded the following: citations without abstracts;
anonymous reports; duplicate studies; case reports or
studies which did not compare outcomes among people
with DM to people without DM; reviews; studies that
did not report outcomes in adults; studies that examined
the reverse association of the impact of TB disease on
DM or diagnosed DM during TB treatment; studies
where the majority of treatment took place prior to
1980, in order to incorporate short course chemother-
apy and assess consistent TB treatment regimens [15];
studies after 1995 that did not adjust for human immu-
nodeficiency virus (HIV) status if study participants
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adults (15 to 49 years) of > 5%; studies that did not
report at least one of the TB outcomes listed above; stu-
dies that did not follow patients for the duration of TB
treatment for the outcome of failure and death; studies
that assessed the risk of relapse that did not follow
patients from the first episode of TB; studies in which
people with DM received different anti-TB treatment
regimens than people without DM; and studies that
either did not provide effect estimates in odds ratios
(ORs), rate ratios, hazard ratios (HRs), or RRs or did
not allow for the computation of these values.
Data extraction and quality assessment
For every study that met our eligibility criteria, two
investigators (MB and JH or CJ) independently collected
detailed information on the year, country, study design,
study population, type of TB outcome, diagnosis of DM
and TB, adjustment for age, HIV and other potential
confounders, proportion of treated patients who experi-
enced the outcomes of interest, effect sizes, and 95%
confidence intervals. Differences were resolved by dis-
cussion and consensus. For non-English language
papers, bilingual translators trained in medicine or pub-
lic health helped classify studies and extract data with
MB and JH.
TB death and relapse are relatively rare events; there-
f o r e ,w ea s s u m e dt h a tO R s ,R R s ,a n dH R sp r o v i d e da
similar risk estimate, and we reported them as a com-
mon effect estimate in the death and relapse analyses
[19].
Data synthesis and analysis
We performed separate analyses for each of the out-
comes and assessed heterogeneity of effect estimates
using the Cochran Q test for heterogeneity and the I
2
statistic described by Higgins et al. [20,21]. The 95%
confidence intervals (CIs) for the I
2 were calculated
using the test-based methods [21]. We performed meta-
analysis to compute a summary estimate only for those
studies that did not show significant heterogeneity,
defined as I
2 < 50% [21]. We decided a priori to use the
random effects model and weighting method according
to the method described by DerSimonian and Laird [22]
as we expected the true effect of DM on TB outcomes
to vary and because it would yield conservative 95% CIs.
We addressed potential causes of heterogeneity and
the impact of study quality for the outcome analyses
with an I
2 >1 0 % .W ec o m p a r e dp o o l e de f f e c te s t i m a t e s
for subgroups categorized by background TB incidence
and pulmonary versus other types of TB, and by the fol-
lowing quality-associated variables: time of assessment
of DM in relation to TB diagnosis, exposure classifica-
tion (self-report, medical records and DM medications
versus laboratory tests), loss to follow-up, and the use of
survival analysis. We considered studies to be of higher
quality if they specified that patients were diagnosed
with DM prior to TB diagnosis, if DM was diagnosed
based on medical records, self-report or use of DM
medications (blood glucose measurements at the time of
TB diagnosis may overestimate DM, as TB disease is
associated with increased blood glucose levels [23,24]), if
studies adjusted for at least age, if they reported loss to
f o l l o w - u pt h r o u g hd e f a u l ta n dt r a n s f e ro u to fl e s st h a n
10% of the cohort, and if they estimated a HR using sur-
vival analysis. We regressed study-specific log-trans-
formed RRs by the variables representing the study
characteristics, weighting the studies by the inverse of
the sum of within-study and between-study variance for
all studies within the comparison. Coefficients of meta-
regression represent differences in log-transformed RRs
between the subgroups. We tested the significance of
these coefficients by Student’s t-test, and the significance
was set at P < 0.05. We performed a separate analysis
for studies assessing the outcome of death that adjusted
for age and other confounding factors.
We assessed publication bias using Begg’sa n dE g g e r ’s
tests [25,26] and by visual inspection for asymmetry of a
plot of the natural logarithms of the effect estimates
against the standard errors [25]. Statistical procedures
were performed using STATA version 10, Texas [27].
Results
We identified and screened 3,623 papers by titles and
abstracts, including 2,841 papers in English and 782
papers in other languages. We excluded 2,881 papers,
because they did not study TB outcomes, studied exclu-
sively surgical interventions, lacked a comparison group,
were studies conducted exclusively among children,
were published before 1980, lacked an abstract, or were
case reports, reviews, or anonymous reports (Figure 1).
The full texts of the remaining 742 papers were ana-
lyzed and on the basis of that review, we excluded 709
articles because they did not present an effect estimate
or provide data from which an effect estimate could be
calculated (142), they did not assess DM (378), they did
not assess the TB outcomes defined in the methods
(74), they lacked a comparison group without DM (49),
they grouped DM with other chronic diseases (26), the
treatment regimen differed between the population with
DM and without DM (5), they were reviews, case
reports, or duplicate studies (24), the majority of treat-
ment took place before 1980 (6), they did not follow
patients from the first episode of TB for the outcome of
relapse (3), or they measured the reverse association
between DM and TB or diagnosed DM after TB diagno-
sis (2). No studies conducted in countries with a high
prevalence of HIV were excluded on the basis of not
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further information and clarification and obtained addi-
tional data from 7 of these. We included 33 studies of
which 9 reported culture conversion at two to three
months, 12 reported the combined outcome of failure
and death, 23 reported death, 4 reported death adjusted
for age and other potential confounding factors, 5
reported relapse, and 4 reported recurrence with drug
resistant tuberculosis (Table 1) [3,11,12,28-57]. The
included studies were written in English (25), Japanese
(4), French (2), and Spanish (2).
Sputum culture conversion at two to three months
We found substantial heterogeneity of effect estimates
among the nine studies that assessed the risk of
remaining sputum culture positive after two to three
months of anti-TB therapy comparing patients with
and without DM (Figure 2). Relative risks ranged from
0.79 to 3.25, and between-study variance accounted for
58% of the total variance among studies. Because of
this heterogeneity, we do not report a summary esti-
mate. We found no evidence for publication bias by
either Begg’st e s t( P = 0.30) or Egger’st e s t( P =0 . 2 7 )
(Additional file 1). Among the three studies that
reported RRs of < 1 for the risk of sputum culture
positivity at two to three months, one reported a sig-
nificant difference in sputum culture conversion at six
months (unadjusted OR 2.69 (95% CI, 1.01 to 7.14),
adjusted OR 7.65 (95% CI, 1.89 to 30.95)) [11], while
another found a trend toward increased time to
Citations excluded based on abstract review (n=2,881) 
 Anonymous  reports  (n=20) 
  No abstract available (n=171) 
Case reports (n=232) 
  Studies with pediatric cohorts (n=190) 
  No assessment of TB outcome (n=1,515) 
  Studies about risk factors for developing TB (n=55) 
 Reviews  (n=526) 
  Studies published before 1980 (n=107) 
  Studies with exclusively surgical outcomes (n=40) 
  Studies exclusively about adherence (n=16) 
  Studies lacking a comparison group (n=9) 
Citations retrieved for more detailed evaluation  
(n=742) 

Citations excluded after full text review (n=709) 
  No assessment of TB outcome (n=74) 
  DM not assessed (n=378) 
Effect estimate of association between DM and TB outcome 
not presented or calculable (n=142) 
Review (n=18) 
Case report (n=4) 
  Studies lacking a control group (n=49) 
  Studies grouping DM with other chronic diseases (n=26) 
  Studies quantifying the reverse association between TB and DM (n=2) 
Studies with >50% of TB treatment prior to 1980 (n=6) 
TB treatment differed systematically between patients with and without  
 DM  (n=5) 
Studies assessing relapse that did not follow patients from first 
episode of TB (n=3) 
Duplicate study (n=2)
Studies included in analysis, by outcome (n=33) 
Culture conversion (n=9) 
Failure and Death (n=12) 
Death, not age-adjusted (n=23) 
Death, with age-adjusted multivariate 
analysis (n=4) 
Relapse (n=5) 
Drug resistant recurrent TB (n=4) 
Potentially relevant citations identified and 
screened for retrieval from PubMed, 
EMBASE, WHO Regional Indexes and key 
bibliographies; duplicates eliminated  
(n=3,623) 
Figure 1 The literature search for studies on the association between DM and TB outcomes.
Baker et al. BMC Medicine 2011, 9:81
http://www.biomedcentral.com/1741-7015/9/81
Page 4 of 15Table 1 Characteristics of included studies for the association between DM and TB outcomes
Outcomes
Study Type of study Country Type of TB Total
n
Population
with DM
n
Sputum
Culture
Conversion
2-3
months
Failure
And
Death
Death Adjusted
Variables for
Death Outcome
Relapse DR
Recurrence
DM Definition
Alisjahbana
[11]
Prospective cohort Indonesia Pulmonary TB 634 94 √√ √ 2 measurements of FBG > 126
mg/dL
Ambrosetti
[28]
Prospective cohort Italy Undifferentiated
TB
778 32 √√ Medical records
Ambrosetti
[29]
Prospective cohort Italy Undifferentiated
TB
838 50 √√ Medical records
Ambrosetti
[30]
Prospective cohort Italy Undifferentiated
TB
715 40 √√ Medical records
Anunnatsiri
[31]
Retrospective cohort Thailand Pulmonary TB 226 117 √ Medical records
Banu Rekha
[32]
Retrospective
analysis of 3
concurrent studies
India Pulmonary TB 190 92 √ Medical records, FBG
Bashar [33] Retrospective case-
control
USA Undifferentiated
TB
155 50 √ Medical records
Blanco [34] Retrospective cohort Canary
Islands,
Spain
Pulmonary TB 98 14 √ Medical records
Centis [35] Prospective cohort Italy Undifferentiated
TB
1,162 56 √√ Medical records
Centis [36] Prospective cohort Italy Undifferentiated
TB
906 40 √√ Medical records
Chiang [37] Retrospective cohort Taiwan Pulmonary TB 1,127 241 √√ Medical records
Dooley [12] Retrospective cohort USA Undifferentiated
TB
297 42 √√ Age, HIV, weight,
foreign birth
Medical records,
non-FBG > 200 mg/dL,
DM medications
Fielder [38] Retrospective cohort USA Pulmonary TB 174 22 √ Age Medical records
Fisher-Hoch
[39]
Retrospective cohort Mexico &
USA
Undifferentiated
TB
2,878 688 √√ Self report
Guler [40] Retrospective cohort Turkey Pulmonary TB 306 44 √ Medical records
Hara [41] Retrospective cohort Japan Pulmonary TB 624 112 √ Medical records
Hasibi [42] Retrospective cohort Iran Disseminated TB 50 6 √ Medical records
Ito [43] Retrospective cohort Japan Undifferentiated
TB
109 16 √ Medical records
Kitahara
[44]
Retrospective cohort Japan Pulmonary TB 520 71 √√ Medical records
Kourbatova
[45]
Retrospective case-
control
Russia Undifferentiated
TB
460 20 √ Medical records
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5Table 1 Characteristics of included studies for the association between DM and TB outcomes (Continued)
Maalej [46] Retrospective case-
control
Tunisia Pulmonary TB 142 60 √√ Medical records
Mboussa
[47]
Retrospective cohort Republic
of the
Congo
Pulmonary TB 132 32 √√ √ 2 measurements of FBG ≥ 126
mg/dL
Oursler [48] Retrospective cohort USA Pulmonary TB 139 18 √ Age, HIV,
renal, COPD
Medical records
Pina [49] Retrospective cohort Spain Undifferentiated
TB
1,511 73 √ Medical records
Ponce-De-
Leon [3]
Prospective cohort Mexico Pulmonary TB 581 172 √√ Medical records (FBG ≥ 126 mg/
dL, non-FBG ≥ 200 mg/dL
sensitivity analysis)
Singla [50] Retrospective cohort Saudi
Arabia
Pulmonary TB 692 187 √√ √ 2 measurements of FBG > 140
mg/dL
Subhash
[51]
Retrospective cohort India Undifferentiated
TB
361 72 √ FBG > 140 mg/dL, medical
records and DM medication or
diet
Tatar [52] Retrospective cohort Turkey Undifferentiated
TB
156 78 √√ Medical records
Vasankari
[53]
Retrospective cohort Finland Pulmonary TB 629 92 √ Treatment with DM medications
Wada [54] Retrospective cohort Japan Pulmonary TB 726 143 √√ Medical records
Wang [55] Retrospective cohort Taiwan Pulmonary TB 453 75 √ Medical records
Wang [56] Retrospective cohort Taiwan Pulmonary TB 217 74 √√ Age, sex Medical records and DM
medication or FBG > 126 mg/dL
Zhang [57] Retrospective
Cohort
China Pulmonary TB 2,141 203 √ FBG ≥ 126 mg/dL
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5sputum culture conversion among patients with dia-
betes (P = 0.09) [12].
The sensitivity analysis presented in Table 2 shows
that the estimated risk of remaining sputum culture
positive at two to three months was greater in studies
that used medical records, patient report and medication
history to classify patients with diabetes, rather than
laboratory tests conducted at the initiation of treatment
(RR 2.22 (95% CI, 1.85 to 2.66) and RR 0.92 (95% CI,
0.62 to 1.38) respectively) (meta-regression P < 0.01).
None of the studies explicitly stated that DM was diag-
nosed prior to TB.
Failure and death
The pooled RR of the combined outcome, failure and
death, among the 12 studies that included both out-
comes was 1.69 (95% CI, 1.36 to 2.12). Between-study
variance accounted for 19% of the total variance (Figure
3). Although Egger’s test suggested publication bias (P =
0.01), Begg’s test was not significant (P = 0.49) (Addi-
tional file 2). The sensitivity analysis did not include sev-
eral of the quality associated strata, because none of the
reviewed studies explicitly stated that the DM diagnosis
predated the TB diagnosis, and none performed a
survival analysis. As shown in Table 2 although some of
the variability among the studies is explained by the
variables included, substantial heterogeneity remains
after the meta-regression.
Death
Among the 23 studies that compared the risk of death
during TB treatment in patients with DM versus
patients without DM, we found moderate heterogeneity
of effect estimates with between study variance account-
ing for 46% of the total variance (Figure 4). The pooled
RR from the random effects analysis was 1.89 (95% CI,
1.52 to 2.36). Although Egger’s test suggested publica-
tion bias (P = 0.01), Begg’s test was not significant (P =
0.19) (Additional file 3). The one study that evaluated
the effect estimate using survival analysis found a HR of
4.8 (95% CI, 2.0 to 11.6) [48]. None of the studies expli-
citly stated that DM was diagnosed prior to TB.
When we restricted the analysis to those four studies
which adjusted for age and other potential confounders,
we did not find heterogeneity among the effect estimates
despite the fact that each study controlled for a different
set of confounders. The random effects pooled OR was
4.95 (95% CI, 2.69 to 9.10) (Figure 5). There was no
Study Country
Population with DM    
Positive sputum
Culture 2-3 months/ 
Total
Population without DM
Positive sputum 
Culture 2-3 months/
Total
RR (95% CI) RR (95% CI)
Kithara, 1994 [44]
Hara, 1996 [41]
Wada 2000 [54]
Japan
Japan
Japan
11/71 (15%)
32/93 (34%)
14/90 (16%)
33/449 (7%)
43/301 (14%)
16/334 (5%)
2.11 (1.12, 3.98)
2.41 (1.62, 3.57)
3 25 (1 65 6 40)
2.11 (1.12, 3.98)
2.41 (1.62, 3.57)
3 25 (1 65 6 40)
Alisjahbana, 2007 [11]
Bl 2007 [34]
Banu Rekha, 2007 [32]
Wada, 2000 [54]
Indonesia
CI l d
India
Japan
7/41 (17%)
4/13 (31%)
8/69 (12%)
14/90 (16%)
68/372 (18%)
13/85 (15%)
10/68 (15%)
16/334 (5%)
0.93 (0.46, 1.90)
2 01 (0 77 5 24)
0.79 (0.33, 1.88)
3.25 (1.65, 6.40)
0.93 (0.46, 1.90)
2 01 (0 77 5 24)
0.79 (0.33, 1.88)
3.25 (1.65, 6.40)
Dooley, 2009 [12] 
Blanco, 2007 [34]
Guler, 2007* [40] 
USA
Canary Islands,
Spain
Turkey
9/30 (30%)
4/13 (31%)
32/44 (73%)
50/163 (31%)
13/85 (15%)
88/262 (34%)
0.98 (0.54, 1.77)
2.01 (0.77, 5.24)
2.17 (1.69, 2.78)
0.98 (0.54, 1.77)
2.01 (0.77, 5.24)
2.17 (1.69, 2.78)
Weights are from random effects analysis
Heterogeneity I-squared = 58% (12, 80)
Tatar, 2009 [52] Turkey 11/55 (20%) 8/53 (15%) 1.33 (0.58, 3.04) 1.33 (0.58, 3.04)
Weights are from random effects analysis
1 .3 1 2 7
Figure 2 Risk of remaining sputum culture positive for TB patients with DM compared with TB patients without DM. Size of the square
is proportional to the precision of the study-specific effect estimates, and the bars indicate the corresponding 95% CIs. *The RR for Guler et al.
[40] was calculated using the OR, CI and total number of patients with and without DM provided in the paper.
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Egger’s test (P = 0.18) (Additional file 4).
Relapse
Among the five studies that assessed the risk of TB
relapse, the random effects pooled RR was 3.89 (95% CI,
2.43 to 6.23) for relapse after TB cure or treatment
completion among patients with DM versus patients
without DM (Figure 6). There was no evidence for het-
erogeneity among the studies that assessed this outcome
and no evidence for publication bias by Begg’st e s t( P =
1.00) or Egger’s test (P = 0.81) (Additional file 5).
Table 2 Sensitivity analysis to identify sources of heterogeneity in the association between DM and TB
TB Outcome Variables Study Characteristics
(No. of studies)
Summary effect
estimates
95% CI I
2 95% CI
I
2
P Value
Heterogeneity
P Value
Meta-
regression
Sputum culture conversion
at 2-3 months
Background TB
incidence
≥ 100,000 (2) 0.87 0.50-1.51 0% NA 0.77 0.53
≥ 10,000 and
< 100,000 (6)
2.22 1.85-2.66 0% 0%-75% 0.70
< 10,000 (1) 0.98 0.54-1.77 NA NA NA
Type of TB Pulmonary (7) 1.91 1.41-2.59 52% 0%-79% 0.05 0.18
Pulmonary and
extrapulmonary (2)
1.08 0.67-1.76 0% NA 0.56
DM diagnosis Patient or medical
report (6)
2.22 1.85-2.66 0% 0%-75% 0.71 < 0.01
Laboratory test (3) 0.92 0.62-1.38 0% 0%-90% 0.92
Loss to follow-
up
< 10% (1) 1.33 0.58-3.04 NA NA NA 0.84
≥ 10% (2) 1.75 0.51-5.95 84% NA 0.01
Failure and Death Background TB
incidence
≥ 100,000 (3) 2.11 1.26-3.53 20% 0%-92% 0.29 0.63
≥ 10,000 and
< 100,000 (6)
1.49 1.23-1.80 0% 0%-75% 0.51
< 10,000 (3) 1.80 0.63-5.13 55% 0%-87% 0.11
Type of TB Pulmonary (7) 1.62 1.26-2.07 26% 0%-68% 0.23 0.49
Pulmonary and
extrapulmonary (5)
2.08 1.27-3.42 6% 0%-80% 0.38
DM diagnosis Patient or medical
report (8)
1.51 1.25-1.82 0% 0%-68% 0.49 0.10
Laboratory diagnosis
(4)
1.97 1.12-3.46 42% 0%-80% 0.16
Loss to follow-
up
< 10% (4) 1.72 1.25-2.37 52% 0%-84% 0.10 0.98
≥ 10% (8) 1.77 1.21-2.59 3% 0%-69% 0.41
Death Background TB
incidence
≥ 100,000 (3) 2.63 0.86-8.02 62% 0%-89% 0.07 0.98
≥ 10,000 and
< 100,000 (13)
1.62 1.33-1.97 8% 0%-60% 0.37
< 10,000 (7) 1.95 1.12-3.40 74% 45%-88% < 0.01
Type of TB Pulmonary (11) 1.97 1.46-2.65 52% 5%-76% 0.02 0.59
Pulmonary and
extrapulmonary (12)
1.84 1.28-2.64 41% 0%-70% 0.07
DM diagnosis Patient or medical
report (18)
1.82 1.42-2.32 50% 15%-71% < 0.01 0.33
Laboratory diagnosis
(5)
2.37 1.49-3.78 1% 0%-79% 0.40
Loss to follow-
up
< 10% (9) 1.43 1.19-1.72 16% 0%-58% 0.30 0.12
≥ 10% (7) 2.22 1.24-3.98 21% 0%-64% 0.27
Survival analysis Survival analysis (1) 4.8 2.0-11.6 NA NA NA 0.18
Alternative analysis (22) 1.81 1.45-2.26 42% 4%-65% 0.02
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Page 8 of 15Drug resistant recurrent disease
The random effects pooled OR was 1.24 (95% CI, 0.72
to 2.16) for the four studies that assessed the odds of
developing recurrent TB that is DR (Figure 7). Studies
were not heterogeneous, as between study variance
accounted for 6% of the total variance among the stu-
dies included in this analysis. We did not find evidence
for publication bias by Begg’st e s t( P = 0.62) or Egger’s
test (P = 0.76) (Additional file 6).
Discussion
This systematic review of the impact of DM on outcomes
of TB treatment determines that DM increases the risk
of the combined outcome of failure and death, death, and
relapse. Notably, the pooled effect estimate for death
among studies that adjusted for age and other confound-
ing factors was found to be higher than the pooled effect
estimate among the unadjusted studies. This finding not
only suggests that patients with DM receiving TB therapy
are at risk for poor outcomes, but that outcome studies
that do not control for appropriate confounders may
underestimate the negative impact of DM in TB patients.
Future studies of the impact of DM on TB outcomes
should be designed to minimize the potential bias due to
confounding factors such as age and HIV.
The results of the studies analyzing culture positivity
at two to three months after initiation of TB treatment
were heterogeneous with five of the nine studies report-
ing an RR of greater than two and three reporting an
RR of less than one. Two of those three papers reported
delay in sputum culture conversion in persons with DM
at some point during the course of treatment [11,12].
Thus, all but one of the papers included in this analysis
reported delay in sputum culture conversion, although
this outcome occurred at different times.
The effect of DM on both the combined outcome of
failure and death and death alone in studies that did not
adjust for age and other confounding factors was rela-
tively modest; however, the effect on death not only per-
sisted, but increased among those studies that adjusted
for potential confounders. An explanation for the higher
risk observed in the studies that adjusted for confound-
ing factors may be that patients who die during TB
treatment have other strong risk factors for death such
as HIV or co-morbidities that tend to reduce the appar-
ent impact of DM in the unadjusted analyses. However,
because the studies that adjusted for confounders were
all performed in industrialized countries where TB mor-
tality rates tend to be high [58], it is difficult to general-
ize these results to higher burden settings.
Study
A b tti 1995 R t [28]
Country 
It l
Population
with DM
Failure and 
Deaths/
Total
3/32 (9%)
Population
without DM
Failure and 
Deaths/
Total
33/737 (4%)
RR (95% CI)
20 9( 06 8 64 7 )
RR (95% CI)
20 9( 06 8 64 7 )
Ambrosetti, 1996 Report [29]
Centis, 1998 Report [35] 
Ambrosetti, 1995 Report[ 2 8 ]
Ambrosetti, 1997 Report [30]
Italy
Italy
Italy
Italy
5/50 (10%)
5/41 (12%)
3/32 (9%)
2/40 (5%)
20/773 (3%)
61/1059 (6%)
33/737 (4%)
45/667 (7%)
3.87 (1.51, 9.87)
2.12 (0.90, 4.99)
2.09 (0.68, 6.47)
0.74 (0.19, 2.95)
3.87 (1.51, 9.87)
2.12 (0.90, 4.99)
2.09 (0.68, 6.47)
0.74 (0.19, 2.95)
Centis, 1999 Report [36] 
Ponce-de-Leon, 2004 [3]
Mboussa, 2003 [47] 
Italy
y
Mexico
Congo
2/40 (5%)
()
42/172 (24%)
13/32 (41%)
28/852 (3%)
()
67/409 (16%)
13/100 (13%)
1.52 (0.38, 6.16)
()
1.49 (1.06, 2.10)
3.13 (1.62, 6.03)
1.52 (0.38, 6.16)
()
1.49 (1.06, 2.10)
3.13 (1.62, 6.03)
Alisjahbana, 2007 [11] 
Singla, 2006 [50] 
Chi 2009 [37]
Anunnatsiri, 2005 [31] 
Indonesia
Saudi
Arabia
Ti
Thailand
8/94 (9%)
1/187 (<1%)
60/241 (25%)
4/38 (11%)
32/540 (6%)
7/505 (1%)
161/886 (18%)
11/188 (6%)
1.44 (0.68, 3.02)
0.39 (0.05, 3.11)
13 7( 10 6 17 8 )
1.80 (0.60, 5.35)
1.44 (0.68, 3.02)
0.39 (0.05, 3.11)
13 7( 10 6 17 8 )
1.80 (0.60, 5.35)
Summary
Heterogeneity I-squared = 19% (0, 58)
Chiang, 2009 [37]
Wang, 2009 [56]  
Taiwan
Taiwan
60/241 (25%)
13/74 (18%)
161/886 (18%)
11/143 (8%)
1.69 (1.36, 2.12)
1.37 (1.06, 1.78)
2.28 (1.08, 4.85)
1.69 (1.36, 2.12)
1.37 (1.06, 1.78)
2.28 (1.08, 4.85)
Weights are from random effects analysis
1 .3 1.69 7
Figure 3 Risk of failure/death for TB patients with DM compared with TB patients without DM. Size of the square is proportional to the
precision of the study-specific effect estimates, and the bars indicate the corresponding 95% CIs. The diamond is centered on the summary RR
of the observational studies, and the width indicates the corresponding 95% CI.
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Page 9 of 15Kith 1994 [44]
Study
J
Country
3/71 (4%)
Population with DM 
Deaths/Total
14/449 (3%)
Population without DM
Deaths/Total
1 36 (0 40 4 60)
RR (95% CI)
1 36 (0 40 4 60)
RR (95% CI)
Centis, 1998 Report [35] 
Kithara, 1994 [44]
Ambrosetti, 1996 Report [29]
Ambrosetti, 1995 Report [28]
Ambrosetti, 1997 Report [30]
Italy
Japan
Italy
Italy
Italy
5/41 (12%)
3/71 (4%)
4/50 (8%)
3/32 (9%)
1/40 (3%)
49/1059 (5%)
14/449 (3%)
19/773 (2%)
29/737 (4%)
43/667 (6%)
2.64 (1.11, 6.26)
1.36 (0.40, 4.60)
3.25 (1.15, 9.20)
2.38 (0.77, 7.41)
0.39 (0.05, 2.74)
2.64 (1.11, 6.26)
1.36 (0.40, 4.60)
3.25 (1.15, 9.20)
2.38 (0.77, 7.41)
0.39 (0.05, 2.74)
Mboussa 2003 [47]
Bashar, 2001 [33] 
Centis, 1999 Report [36]
Fielder, 2002 [38]
Oursler, 2002 [48]
Congo
USA
Italy
USA
USA
8/32 (25%)
7/50 (14%)
2/40 (5%)
13/22 (59%)
8/18 (44%)
8/100 (8%)
1/105 (1%)
26/852 (3%)
29/152 (19%)
14/108 (13%)
3 13 (1 28 7 65)
14.70 (1.86, 116)
1.64 (0.40, 6.66)
3.10 (1.92, 4.99)
3.43 (1.68, 6.98)
3 13 (1 28 7 65)
14.70 (1.86, 116
1.64 (0.40, 6.66)
3.10 (1.92, 4.99)
3.43 (1.68, 6.98)
Singla, 2006 [50] 
Kourbatova, 2006 [45] 
Pina, 2006 [49] 
Mboussa, 2003 [47]
Ponce-de-Leon, 2004 [3]
Saudi Arabia
Russia
Spain
Congo
Mexico
1/187 (<1%)
5/20 (25%)
8/73 (11%)
8/32 (25%)
34/172 (20%)
3/505 (<1%)
87/440 (20%)
97/1438 (7%)
8/100 (8%)
61/409 (15%)
0.90 (0.09, 8.60)
1.26 (0.58, 2.76)
1.62 (0.82, 3.21)
3.13 (1.28, 7.65)
1.33 (0.91, 1.94)
0.90 (0.09, 8.60)
1.26 (0.58, 2.76)
1.62 (0.82, 3.21)
3.13 (1.28, 7.65)
1.33 (0.91, 1.94)
Vasankari, 2007 [53]
Hasibi, 2008 [42] 
Alisjahbana, 2007 [11] 
Chiang 2009 [37]
Fisher-Hoch, 2008 [39] 
Finland
Iran
Indonesia
Taiwan
USA
22/92 (24%)
3/6 (50%)
2/94 (2%)
52/241 (22%)
46/391 (12%)
86/537 (16%)
6/44 (14%)
0/540 (0%)
137/886 (15%)
112/1022 (11%)
1.49 (0.99, 2.26)
3.67 (1.23, 10.93)
28.47 (1.38, 588
1 40 (1 05 1 86)
1.07 (0.78, 1.48)
1.49 (0.99, 2.26)
3.67 (1.23, 10.93)
28.47 (1.38, 588)
1 40 (1 05 1 86)
1.07 (0.78, 1.48)
Tatar, 2009 [52] 
Maalej, 2009 [46] 
Wang, 2009 [56] 
Dooley, 2009 [12] 
Chiang, 2009 [37]
Turkey
Tunisia
Taiwan
USA
Taiwan
2/78 (3%)
2/57 (4%)
13/74 (18%)
6/42 (14%)
52/241 (22%)
0/78 (0%)
0/82 (0%)
11/143 (8%)
20/255 (8%)
137/886 (15%)
5.00 (0.24, 102)
7.16 (0.35, 146)
2.28 (1.08, 4.85)
1.82 (0.78, 4.27)
1.40 (1.05, 1.86)
5.00 (0.24, 102)
7.16 (0.35, 146)
2.28 (1.08, 4.85)
1.82 (0.78, 4.27)
1.40 (1.05, 1.86)
Weights are from random effects analysis
Summary
Heterogeneity I-squared = 46% (12, 67) 
1.89 (1.52, 2.36) 1.89 (1.52, 2.36)
1 .3 1.89 7
Figure 4 Risk of death for TB patients with DM compared with TB patients without DM. Size of the square is proportional to the precision
of the study-specific effect estimates, and the bars indicate the corresponding 95% CIs. The diamond is centered on the summary RR of the
observational studies, and the width indicates the corresponding 95% CI.
Study   OR (95% CI)
Population 
with DM
Deaths/
Total
Population 
without DM
Deaths/
Total
Country
Fielder, 2002 [38]  USA 13/22 (59%) 29/152 (19%) 3.80 (1.42, 10.16)
Dooley, 2009 [12] 
Oursler, 2002 [48]   
USA
USA
6/42 (14%)
8/18 (44%)
20/255 (8%)
14/108 (13%)
6.50 (1.11, 38.20)
6.70 (1.57, 28.52)
Summary
Wang, 2009 [56]   Taiwan13/74 (18%) 11/143 (8%)
4.95 (2.69, 9.10)
5.20 (1.77, 15.25)
Weights are from random effects analysis
1 1 4.95 15 40
Heterogeneity I-squared = 0% (0, 85)
Figure 5 Adjusted odds of death for TB patients with DM compared with TB patients without DM. Size of the square is proportional to
the precision of the study-specific effect estimates, and the bars indicate the corresponding 95% CIs. The diamond is centered on the summary
OR of the observational studies, and the width indicates the corresponding 95% CI.
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Page 10 of 15Study Country  RR (95% CI) RR (95% CI)
Population
with DM
Relapse/
Total
Population
without DM
Relapse/
Total
Wada, 2000 [54] 
Mboussa, 2003 [47]
Japan
Congo
7/61 (11%)
6/17 (35%)
4/284 (1%)
9/77 (12%)
8.15 (2.46, 26.97)
3.02 (1.24, 7.35)
8.15 (2.46, 26.97)
3.02 (1.24, 7.35)
Singla, 2006 [50] 
Maalej, 2009 [46]  
Saudi 
Arabia
Tunisia
2/130 (2%)
4/55 (7%)
3/367 (1%)
1/82 (1%)
1.88 (0.32, 11.14)
5.96 (0.68, 51.95)
1.88 (0.32, 11.14)
5.96 (0.68, 51.95)
Summary
Zhang, 2009 [57]   China 33/165 (20%) 9/170 (5%)
3.89 (2.43, 6.23)
3.78 (1.87, 7.65)
3.89 (2.43, 6.23)
3.78 (1.87, 7.65)
Weights are from random effects analysis
Heterogeneity  I-squared = 0% (0, 79)
1 .3 1 3.89 15 60
Figure 6 Risk of TB relapse for TB patients with DM compared with TB patients without DM. Size of the square is proportional to the
precision of the study-specific effect estimates, and the bars indicate the corresponding 95% CIs. The diamond is centered on the summary RR
of the observational studies, and the width indicates the corresponding 95% CI.
Study Country OR (95% CI)
Population 
with DM 
DR Recurrent TB/
Recurrent TB
Population 
without DM 
DR Recurrent TB/
Recurrent TB
Wang, 2001 [55]   Taiwan 3/25 (12%) 27/173 (16%) 0.80 (0.17, 3.67)
Recurrent TB Recurrent TB
Subhash, 2003 [51] 
Ito, 2004 [43]
Fisher Hoch 2008 [39]
India
Japan
Mexico
20/28 (71%)
2/16 (13%)
11/24 (46%)
106/145 (73%)
16/93 (17%)
14/64 (22%)
0.92 (0.37, 2.27)
0.69 (0.14, 3.37)
30 0( 11 0 81 9 )
Fisher-Hoch, 2008 [39]  -
Fisher-Hoch, 2008 [39] -
USA
Mexico
3/23 (13%)
11/24 (46%)
6/51 (12%)
14/64 (22%)
1.24 (0.72, 2.16)
1.10 (0.27, 4.49)
3.00 (1.10, 8.19)
Summary
Weights are from random effects analysis
1 1 4 12 4 5 10
Heterogeneity I-squared = 6% (0, 80)
1 .1 .4 1.24 5 10
Figure 7 Odds of recurrent TB that is DR, comparing patients with DM to patients without DM. Size of the square is proportional to the
precision of the study-specific effect estimates, and the bars indicate the corresponding 95% CIs. The diamond is centered on the summary OR
of the observational studies, and the width indicates the corresponding 95% CI.
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Page 11 of 15We expect that the risks of the combined outcome,
failure and death, and death alone are underestimated
due to loss to follow-up. The patients who default or
are transferred out are not followed for the entire treat-
ment period, and their final outcome is therefore not
observed. In the one study that used survival analysis to
a d j u s tf o rt h i sl o s so ff o l l o w - u p ,t h eH R sw e r eh i g h e r
than the pooled effect estimates in both the univariate
and adjusted analyses [48]. Since the rate of death is
higher among persons with DM than those without at
baseline, the increased death rate may reflect that risk
rather than indicate a higher rate of TB associated mor-
tality among those with DM [59]. However, the differen-
tial age specific mortality experienced by persons with
DM probably does not account for the odds ratio of
death of almost 5 in the adjusted analysis.
Although we found evidence for publication bias in
the analysis of the combined outcome, failure and death,
and the unadjusted analysis of death when we used
Egger’s test, this was not confirmed with Begg’st e s t ,a
method that is less susceptible to false positive results
[60,61], nor was it found in the analysis of death
restricted to studies that adjusted for age and other
confounders.
Patients with DM were four times more likely to
develop a relapse of TB disease than patients without
DM. Considering the fact that these individuals were
considered cured or treatment complete, the patients
could have relapsed through one of two possible
routes: they may have been cured but experienced a
recurrence of the former infection, or they may have
been re-infected with a new strain of TB. The
increased risk of recurrent disease in either of these
scenarios is consistent with prior evidence suggesting
that those with DM are at increased risk of developing
TB disease [3-6]. Furthermore, health facility exposure
to TB, an important contributor to the total TB infec-
tion risk in people living with HIV [62], may contri-
bute to the risk of re-infection in patients with DM
due to repeated attendance at health facilities for dia-
betes management.
The results in this systematic review may underesti-
mate the risk of relapse, because patients with DM are
more likely to die during a first course of TB therapy
and in the time period prior to a diagnosis of relapse
[63]. Thus, patients with DM may be less likely to have
recurrent TB than patients without DM because of loss
to competing risks. This methodological consideration
suggests that the appropriate study design to assess
relapse is survival analysis, and only one of the studies
reported here used that approach [54]. Other limitations
of this analysis included the small numbers of relapses
that occurred and lack of adjustment for confounding
factors.
W ef o u n dn oe v i d e n c et h a tD Mi n c r e a s e dt h er i s ko f
recurrent disease with DR TB, despite the greater risk
for TB disease and impaired cell mediated immunity
[64-68]. This finding is consistent with data from a
recent pharmacological study that reported therapeutic
levels of rifampicin, pyrazinamide and ethambutol in
patients with DM who received standard dosing during
the intensive phase of TB treatment [69]. However, if
the effect of DM is relatively small, the four studies with
only 208 cases of DR recurrent disease may not have
had sufficient power to detect an association. Further-
more, these studies did not adjust for potential con-
founding factors such as HIV or frequency of medical
care during TB treatment.
The increased risks of failure, death during TB treat-
ment, and relapse among patients with DM are consis-
tent with data from mouse models and human studies
that show that DM impairs cell-mediated immunity
[64-68]. Furthermore, a study by Restrepo et al. deter-
mines that poor diabetic control, as measured by glyco-
sylated hemoglobin level, affects in vitro innate and type
1 cytokine responses [70]. We speculate that poor dia-
betes control, possibly exacerbated by TB disease, may
be an important contributing factor to case fatality and
relapse.
This study highlights the perils of using observational
studies for a meta-analysis. Although meta-analyses of
observational studies are frequently faulted for finding
false statistically significant associations by combining
small studies affected by confounding [71], we found
evidence that an association may also be diminished by
confounding or bias resulting from study design. Mis-
classification of the diagnosis of DM may have also
diminished the association between DM and TB out-
come. Since glucose levels are transiently increased in
the setting of active TB [23,24], and the studies did not
specify that the diagnosis of DM must precede that of
TB, some patients diagnosed with DM may have been
experiencing only a transient episode of hyperglycemia.
The systematic review highlights the need for large-scale
prospective studies with appropriate study design, pro-
spective diagnoses of diabetes, control for confounding
factors, and clear TB outcomes to further clarify the
strength of the associations.
Conclusions
This study reports that diabetes is associated with an
increased risk of the combined endpoint of failure and
death, death during TB treatment, and relapse. It is the
first study that we are aware of that quantifies the associa-
tions based on a systematic review of the literature. The
implications of the negative impact of DM on TB out-
comes include poor individual outcomes, increased risk of
secondary transmission, and increased incidence of TB
Baker et al. BMC Medicine 2011, 9:81
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Page 12 of 15disease. Considering the increasing burden of DM, parti-
cularly in areas with highly prevalent TB, TB control pro-
grams will need to expand efforts to focus on treatment
and monitoring of patients with DM and TB disease.
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95% confidence limits for all studies with sputum cultures at two to
three months.
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95% confidence limits for all studies with recurrent TB that is DR.
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